Navigation Links
New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development

SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled Thought Leader Insight & Analysis: Rheumatoid Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress in developing biological and small molecule regimens for the treatment of early RA.

According to this report, the key change in practice occurring in the treatment of RA is the push toward earlier diagnosis and treatment, which is associated with more durable remission. New biomarkers and approaches to cellular imaging in early disease are also being investigated.

"Our Panel sheds light on which companies are likely to be positioned to capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In addition, they offer predictions on how tocilizumab, certolizumab and golimumab will compete with the established biologicals, and how the current market leaders are positioning to defend their brands in the RA space. Their discussion will provide essential strategic and competitive insight for anyone with a stake in this market."

The report also addresses pain management in RA, provides a postmortem on the rituximab non-renal lupus trial, and discusses the most meaningful clinical developments related to the following mechanisms: Anti-TNF, Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase, JAK, Syk, PDE5, and more.

Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma, Pfizer, Roche/Chugai, Roche/Gen

SOURCE MedPredict Market Research
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
2. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
3. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
4. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
5. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
6. Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report
7. Galaxy Nutritional Foods Reports FY2008 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
10. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
11. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: